Satellos Bioscience Inc. (MSLE) - What Are Brokerages Thinking About This Stock?

Key Points

  • Analysts have a “Moderate Buy” consensus on Satellos Bioscience, with six buy ratings and two sell ratings among eight analysts. Their average 12-month price target is $20.60.
  • Satellos reported a quarterly loss of $0.53 per share, missing analysts’ $0.44 loss estimate. Shares opened at $6.47, below their 50- and 200-day moving averages.
  • Stonepine Capital Management increased its Satellos holdings by 391.6% in the second quarter, to 491,624 shares, or about 2.36% of the company.
  • Five stocks to consider instead of Satellos Bioscience.

Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.60.

A number of brokerages have commented on MSLE. Craig Hallum began coverage on Satellos Bioscience in a report on Thursday, October 8th. They set a "buy" rating and a $24.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Wall Street Zen upgraded Satellos Bioscience from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Zacks Research downgraded Satellos Bioscience from a "hold" rating to a "strong sell" rating in a research note on Wednesday, October 21st.

Get Our Latest Research Report on Satellos Bioscience

Satellos Bioscience Stock Down 2.4%

Shares of NASDAQ MSLE opened at $6.47 on Tuesday. The firm has a market cap of $137.29 million, a price-to-earnings ratio of -3.10 and a beta of 1.63. The company's 50-day simple moving average is $7.72 and its 200-day simple moving average is $8.18. Satellos Bioscience has a 52-week low of $5.44 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Equities research analysts anticipate that Satellos Bioscience will post -1.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC increased its holdings in shares of Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) by 391.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 491,624 shares of the company's stock after acquiring an additional 391,624 shares during the quarter. Satellos Bioscience comprises 0.0% of Stonepine Capital Management LLC's investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent SEC filing.

Satellos Bioscience Company Profile

(Get Free Report)

Satellos Bioscience is a biotechnology company developing treatments intended to improve the body's ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company's lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.

Featured Stories

Analyst Recommendations for Satellos Bioscience (NASDAQ:MSLE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Satellos Bioscience Right Now?

Before you consider Satellos Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Satellos Bioscience wasn't on the list.

While Satellos Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines